Allergy Diagnostics Market Size and Growth Report – Industry Analysis, Share, Trends & Forecasts (2024 - 2029)

Market Size and Share Analysis:

By allergen, the food allergens segment is anticipated to grow with the most significant growth rate of 12.56% in the forecast period. In 2024, the consumables within the product segment are expected to dominate the market, accounting for 65.33% of the share. Market size analysis indicates it will grow to USD 7.17 billion by 2029. Further, in 2024, the diagnostic laboratories within the end-user segment are anticipated to lead the market with a 46.81% share. Market analysis suggests that the market size of this allergy diagnostics segment will expand to USD 5.19 billion by 2029. By Test Type, the in-vitro allergy tests segment accounts for the largest share of the market. As allergies become increasingly prevalent, the market is poised for growth.

Data released by Allergy & Anaphylaxis Australia in May 2023 highlighted that Australia has one of the world's highest rates of food allergies, and this trend is accelerating. The report also noted that in 2022, over 500,000 Australians were diagnosed with food allergies, with many more likely undiagnosed. Therefore, the rising prevalence of allergies and the rising allergies due to new allergens are expected to boost the allergy diagnostics market growth during the forecast period.

Furthermore, the increasing number of product launches by the market players is expected to increase the availability of advanced products, thereby boosting the market’s growth. For instance, in May 2023, Dr. Dangs unveiled Allergynius Dx, a groundbreaking test harnessing artificial intelligence (AI) to diagnose allergies in India. This cutting-edge molecular allergy diagnostic, rooted in microarray technology, provides reports that empower both patients and doctors in making informed decisions for allergy management. Hence, the rise in innovation is anticipated to propel the market growth in the coming years.

Overview of Market Segments Covered:

In 2024, inhaled allergens are likely to dominate the allergen segment, capturing a significant 43.51% market share. Projections indicate this segment will grow to an estimated USD 4.59 billion by 2029. Inhaled allergens often lead to allergic rhinitis, commonly known as hay fever. Thus, diagnosis of inhaled allergens is crucial in allergy diagnostics to provide proper and specific medical care to an individual. According to the research study published in Frontiers in Medicine Journal in April 2022, approximately 400 million individuals worldwide suffer from allergic rhinitis (AR) in a year. The condition impacts around 25% of children and 40% of adults. Notably, the incidence rate of AR in children during their first five years stands at 17.2%, with diagnoses peaking between 24 and 29 months. Given that allergic rhinitis is predominantly triggered by inhaled allergens, a growing demand for diagnostic tools targeting these allergens is anticipated in the coming years.

The allergy diagnostics market is segmented by allergen, product, test type, and end user. By allergen, the market is segmented into inhaled allergens, food allergens, and other allergens. By product, the market is segmented into instruments, consumables, and luminometers. Consumables refer to the various materials and products that are used during diagnostic procedures. These consumables are used during different types of allergy tests, such as skin prick tests and blood tests. By test type, the market is segmented into in-vivo allergy tests and in-vitro allergy tests. By end user, the market is segmented into diagnostic laboratories, hospitals, and other end users. Equipped with advanced tools, diagnostics laboratories ensure the reliability of allergy tests. Their expertise not only allows for precise test execution and interpretation but also enhances the overall understanding and management of allergic conditions.

Regional Market Scope of this Report:

In 2024, North America is expected to dominate the market, capturing a significant 45.06% of global allergy diagnostics market share. Projections indicate this North America market value will grow to an estimated USD 4.78 billion by 2029, witnessing significant growth. This surge is driven by several factors: a rising incidence of allergic diseases, environmental pollution, increased government funding, and intensified activities from companies in the sector. For instance, according to the Asthma and Allergy Foundation Report 2022, more than 50 million Americans suffer from various types of allergies every year. The most common allergic condition is seasonal allergic rhinitis or hay fever. As per the same source mentioned above, about 7.7% of adults and 7.2% of children are diagnosed with seasonal allergic rhinitis every year. Furthermore, for instance, the Canadian Government allocated a budget for the treatment and diagnosis of allergies, which is likely to create a demand for diagnostics tests, thereby boosting the market’s growth. For instance, in May 2023, the Canadian Society of Allergy and Clinical Immunology (CSACI) allocated USD 4.5 million to initiate the National Food Allergy Action Plan, which, once fully funded and implemented, will save lives, reduce food allergy prevalence, lower healthcare costs, reduce the economic impact, and improve the quality of life for the millions of impacted Canadians. Hence, owing to these factors, the allergy diagnostics market size in North America is expected to propel in the forecast period.

By geography, the market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). Due to rising allergy prevalence, urbanization, and enhanced healthcare access, the Asia-Pacific and Middle East regions, especially its emerging markets, is poised to see a surge in demand for allergy diagnostic tests. The allergy diagnostic industry size is expected to be high in the North America and Europe regions in the coming years.

Competitive Landscape and Ecosystem Analysis:

Some of the key players in the market are BioMerieux SA, Danaher Corporation, Abionic SA, HOB Biotech Group Corp. Ltd, HYCOR Biomedical, Lincoln Diagnostics Inc., Omega Diagnostics Group PLC, Siemens Healthineers AG, Stallergenes Greer Ltd, Thermo Fischer Scientific Inc., Revvity Inc. (PerkinElmer Inc.), R-Biopharm AG, Immunodiagnostic Systems Holdings PLC (IDS), Biomerica, Inc., among others. The key market players are involved in various strategic activities such as partnerships, product launches, and agreements, which are further expected to bolster the market growth. For instance, in August 2022, Thermo Fisher Scientific announced that the United States Food & Drug Administration (FDA) had approved ImmunoCAP Specific IgE Allergen components for in vitro diagnostic procedures for wheat and sesame allergies. For patients at risk of a severe allergic reaction, these cutting-edge blood tests are expected to serve as diagnostic tools, assisting healthcare professionals in identifying wheat and sesame allergies. The allergy diagnostics industry is moderately fragmented and consists of several market players.